Genentech earned FDA approval for a new method of administering its 0.3 milligram eye drug Lucentis March 21.
Here are three things to know.
1. The drugmaker will now offer a 0.3 milligram prefilled syringe of Lucentis to treat diabetic macular edema and diabetic retinopathy.
2. Lucentis is intended to be injected once a month by a healthcare professional and used along with good diabetic blood sugar control.
3. Genentech expects the Lucentis 0.3 milligram prefilled syringe to hit the market in the second quarter of 2018.
Editor's note: This article was updated March 23 at 8:00 am.